MAIA Biotechnology, Inc., (NYSE American: MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that an abstract ...
Following the presentations, each poster will be available on the Publications page of Liquidia's website at https://liquidia.com/publications.
Altis's AI Model Outperforms RECIST 1.1 in Predicting Overall Survival These findings showcase IPRO-Δ's potential to accelerate clinical d ...
Update on IND-enabling data for MP0712, a Radio-DARPin targeting DLL3 and labeled with 212Pb, co-developed with Orano Med; entering FIH studies ...
BNT327 combined with chemotherapy showed an overall response rate of 85.4% when used as a first-line treatment for ...
The company will deliver an oral presentation on ADRX-0405, its clinical-stage STEAP1 ADC, and a poster presentation on ADRX-0134, its preclinical Na ...
Q4 2024 Earnings Call Transcript March 27, 2025 BioAtla, Inc. beats earnings expectations. Reported EPS is $-0.285, ...
Upcoming mystery film “LOST” has unveiled a new poster! “LOST” follows the unexpected journey of two individuals—one, the son ...
The full abstract will be published online on April 25, 2025. More details about the programs for the AACR Annual Meeting 2025 are available online at AACR Annual Meeting 2025 | Meetings | AACR.
Novel trispecific T cell engager, ZW209, demonstrates potent preclinical efficacy against DLL3-expressing tumors and an encouraging safety profile New antibody-drug conjugate (ADC) candidate, ZW327 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback